Conditions

This post was originally published on this site A U.S. Department of Health and Human Services grant will fund research at two universities into whether an ultrasound technology might be more effective than mammography at detecting breast cancer, particularly in younger people. At present, mammography is most often used to screen for and diagnose breast cancers.…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ImmunityBio‘s interleukin-15 (IL-15) agonist N-803, in combination with Bacillus Calmette-Guerin (BCG) for the treatment of non-muscle invasive bladder carcinoma in situ (CIS) that does not respond to BCG treatment alone. The designation is intended…

This post was originally published on this site “Oh, by the way,” she said nonchalantly as I entered the room. “Your scans are clear.” “I’m sorry, what?” I stuttered in disbelief. Just like that, in a matter of seconds, my oncologist revealed the news I had waited, hoped, and prayed over a year for. Four…

This post was originally published on this site The lungs of patients with sarcoidosis are burdened with a more active subset of immune T-cells, called mucosal-associated invariant T (MAIT) cells, a study reports. The activity of these MAIT cells correlates with worse disease, supporting their potential as therapeutic targets, the researchers said. The study, “Activation…

This post was originally published on this site Bristol-Myers Squibb‘s arthritis medicine Orencia (abatacept) has been named Breakthrough Therapy by the U.S. Food and Drug Administration for the prevention of acute graft-versus-host disease (GvHD) in patients who received a stem cell transplant from an unrelated donor, the company has announced. The designation intends to accelerate…

This post was originally published on this site Adding the antibody Darzalex (daratumumab) to Venclexta (venetoclax), a lymphoma and leukemia treatment, is a promising approach for multiple myeloma patients who failed prior treatment, particularly those with a common genetic abnormality called t(11;14), new Phase 1/2 data show. The combination reduced tumor burden in nearly all — 92%…

This post was originally published on this site With a $544,360 developmental grant from the U.S. Department of Defense (DoD), four research teams are joining efforts to identify biomarkers of ovarian cancer with a goal of detecting the disease earlier or before it even develops. The collaboration, named DoD and SPORE Ovarian Cancer Omics Consortium,…

This post was originally published on this site Common treatments for diabetes don’t appear to mask or reduce levels of a prostate cancer marker in the blood. Rather, the lower rates of prostate cancer detected in men with diabetes might be because they are less likely to undergo prostate biopsies, a large population-based study from…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Foundation Medicine’s FoundationOne CDx as a companion diagnostic test for identifying advanced breast cancer patients with a PIK3CA mutation suitable for treatment with Piqray (alpelisib). Piqray was approved in May, in combination with Faslodex (fulvestrant), for postmenopausal women and…

This post was originally published on this site BeyondSpring’s single-blinded trial design, in which patients are unaware of the treatment they receive, effectively prevented participants from prematurely withdrawing from the company’s DUBLIN-3 study due to dissatisfaction with their treatment allocation, an analysis shows. The findings were presented in a poster, titled “Validation of a Single-Blinded…